Drugs Made In America Acquisition Corp. (DMAA) — SEC Filings

Drugs Made In America Acquisition Corp. (DMAA) — 4 SEC filings. Latest: 425 (May 5, 2026). Includes 2 8-K, 1 425, 1 10-K.

View Drugs Made In America Acquisition Corp. on SEC EDGAR

Overview

Drugs Made In America Acquisition Corp. (DMAA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 8, 2026: Drugs Made In America Acquisition Corp. (DMAA) filed an 8-K on April 8, 2026, disclosing a Letter of Intent (LOI) related to a potential acquisition. The filing includes Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits), with the LOI attached as Exhibit 10.1.

Sentiment Summary

Across 4 filings, the sentiment breakdown is: 4 neutral. The dominant filing sentiment for Drugs Made In America Acquisition Corp. is neutral.

Filing Type Overview

Drugs Made In America Acquisition Corp. (DMAA) has filed 1 425, 2 8-K, 1 10-K with the SEC between Apr 2026 to May 2026.

Recent SEC Filings (4)

Drugs Made In America Acquisition Corp. SEC Filing History
DateFormDescriptionRisk
May 5, 2026425425 Filing
May 5, 20268-K8-K Filing
Apr 15, 202610-K10-K Filing
Apr 8, 20268-KDMAA Files 8-K with Letter of Intentmedium

Risk Profile

Risk Assessment: Of DMAA's 1 recent filings, 0 were flagged as high-risk, 1 as medium-risk, and 0 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Top Tags

acquisition (1) · letter-of-intent (1) · 8-k (1)

Frequently Asked Questions

What are the latest SEC filings for Drugs Made In America Acquisition Corp. (DMAA)?

Drugs Made In America Acquisition Corp. has 4 recent SEC filings from Apr 2026 to May 2026, including 2 8-K, 1 425, 1 10-K. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of DMAA filings?

Across 4 filings, the sentiment breakdown is: 4 neutral. The dominant sentiment is neutral.

Where can I find Drugs Made In America Acquisition Corp. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Drugs Made In America Acquisition Corp. (DMAA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Drugs Made In America Acquisition Corp.?

Financial highlights for Drugs Made In America Acquisition Corp. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.

What is the investment thesis for DMAA?

Investment thesis data for DMAA will be available once enriched filings are processed.

Who are the key executives at Drugs Made In America Acquisition Corp.?

Executive information for Drugs Made In America Acquisition Corp. is extracted from SEC filings as they are enriched with AI analysis.

What are the main risk factors for Drugs Made In America Acquisition Corp. stock?

Of DMAA's 1 assessed filings, 0 were flagged high-risk, 1 medium-risk, and 0 low-risk.

What are recent predictions and forward guidance from Drugs Made In America Acquisition Corp.?

Forward guidance and predictions for Drugs Made In America Acquisition Corp. are extracted from SEC filings as they are enriched.

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.